Citigroup Has Lowered Expectations for Stryker (NYSE:SYK) Stock Price

Posted by Stanley Muller on Oct 30th, 2026

Stryker (NYSE:SYK – Get Free Report) had its price objective dropped by equities research analysts at Citigroup from $360.00 to $315.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the medical technology company’s stock. Citigroup‘s target price indicates a potential upside of 8.04% from the company’s previous close.

A number of other research analysts also recently issued reports on SYK. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Johnson Rice cut shares of Stryker to a “hold” rating in a report on Friday. Finally, Citizens Jmp decreased their target price on Stryker from $400.00 to $390.00 and set a “market outperform” rating for the company in a research note on Friday. Seventeen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $355.84.

Check Out Our Latest Stock Report on SYK

Stryker Stock Performance

Shares of SYK stock traded down $20.19 on Friday, hitting $291.56. 6,437,706 shares of the stock traded hands, compared to its average volume of 2,473,643. The company’s fifty day moving average is $293.56 and its 200 day moving average is $324.86. Stryker has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a market capitalization of $111.83 billion, a PE ratio of 30.21, a PEG ratio of 1.96 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. During the same period in the prior year, the firm earned $3.19 EPS. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, equities research analysts predict that Stryker will post 14.93 earnings per share for the current fiscal year.

Insider Activity at Stryker

In related news, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last ninety days. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AIA Group Ltd increased its holdings in shares of Stryker by 230.4% during the third quarter. AIA Group Ltd now owns 46,593 shares of the medical technology company’s stock valued at $12,831,000 after purchasing an additional 32,493 shares during the period. Provenance Wealth Advisors LLC lifted its holdings in Stryker by 1,376.5% in the third quarter. Provenance Wealth Advisors LLC now owns 3,455 shares of the medical technology company’s stock worth $951,000 after purchasing an additional 3,221 shares during the period. Associated Banc Corp acquired a new stake in Stryker in the third quarter worth about $5,488,000. Integrity Alliance LLC. lifted its holdings in Stryker by 14.7% in the third quarter. Integrity Alliance LLC. now owns 2,313 shares of the medical technology company’s stock worth $637,000 after purchasing an additional 296 shares during the period. Finally, Integrity Advisory Solutions LLC grew its position in Stryker by 24.0% in the 3rd quarter. Integrity Advisory Solutions LLC now owns 1,282 shares of the medical technology company’s stock valued at $353,000 after buying an additional 248 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Key Stryker News

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Analysts remain broadly constructive despite lowering estimates. RBC, Barclays, Citizens JMP and BTIG reduced their price targets but maintained Outperform, Overweight, Market Outperform or Buy ratings, indicating potential upside from recent levels. RBC price target article
Neutral Sentiment: Third-quarter revenue increased 7.6% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19. Management highlighted strength in MedSurg, margin improvement and continued investment in robotic surgery, but those positives were overshadowed by weaker areas of the business. Stryker third-quarter results
Negative Sentiment: Stryker missed Wall Street expectations, reporting $3.52 in EPS versus approximately $3.55–$3.56 expected and $6.52 billion in revenue versus about $6.62 billion expected. The company also cut its 2026 forecast to 6.5%–7.0% organic sales growth and $14.80–$14.90 in adjusted EPS, down from prior guidance of 8.3%–9.3% sales growth and $14.95–$15.10 EPS. Stryker earnings and revenue miss
Negative Sentiment: Investors remain concerned that weaker joint-replacement demand, supply disruptions and a previously unresolved manufacturing issue affecting peripheral vascular products could pressure sales into 2027. The disclosure has prompted scrutiny of the company’s execution, particularly as a new CEO takes over. Stryker peripheral vascular problems
Negative Sentiment: Canaccord downgraded Stryker from Buy to Hold and cut its price target from $385 to $300, reinforcing concerns that the guidance reduction reflects more than a temporary earnings setback. Canaccord Stryker rating

About Stryker

(Get Free Report)

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.